Expression parameters of the polycomb group proteins BMI1, SUZ12, RING1 and CBX7 in urothelial carcinoma of the bladder and their prognostic relevance

Tumor Biology

Volumn 29, Issue 5, 2008, Pages 323-329

  Hinz, S ^a   Kempkensteffen, C ^a   Christoph, F ^a   Krause, H ^a   Schrader, M ^a   Schostak, M ^a   Miller, K ^a   Weikert, S ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Bladder cancer; BMI1; CBX7; Epigenetic regulation; Polycomb group proteins; RING1; SUZ12

Indexed keywords

BMI1 PROTEIN; CBX7 PROTEIN; POLYCOMB GROUP PROTEIN; RING1 PROTEIN; SUZ1 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; DIAGNOSTIC VALUE; EPIGENETICS; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PARAMETER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

EID: 55149119362     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000170879     Document Type: Article

References (34)

1. Holmang S, Hedelin H, Anderstrom C, Holmberg E, Busch C, Johansson SL: Recurrence and progression in low grade papillary urothelial tumors. J Urol 1999;162:702-707.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ: Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130.
3. Chopin DK, Gattegno B: Superficial bladder tumors. Eur Urol 2002;42:533-541.
4. Tiguert R, Fradet Y: New diagnostic and prognostic tools in bladder cancer. Curr Opin Urol 2002;12:239-243.
5. Schulz WA: Understanding urothelial carcinoma through cancer pathways. Int J Cancer 2006;119:1513-1518.
6. Christoph F, Weikert S, Kempkensteffen C, Krause H, Schostak M, Miller K, Schrader M: Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder. Int J Cancer 2006;119:1396-1402.
7. Cote RJ, Datar RH: Therapeutic approaches to bladder cancer: identifying targets and mechanisms. Crit Rev Oncol Hematol 2003;46(suppl):S67-S83.
8. Hinz S, Kempkensteffen C, Weikert S, Schostak M, Schrader M, Miller K, Christoph F: EZH2 polycomb transcriptional repressor expression correlates with methylation of the APAF-1 gene in superficial transitional cell carcinoma of the bladder. Tumour Biol 2007;28:151-157.
9. Gil J, Bernard D, Peters G: Role of polycomb group proteins in stem cell self-renewal and cancer. DNA Cell Biol 2005;24:117-125.
10. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K: EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003;22:5323-5335.
11. Jenuwein T, Allis CD: Translating the histone code. Science 2001;293:1074-1080.
12. Muller J, Hart CM, Francis NJ, Vargas ML, Sengupta A, Wild B, Miller EL, O'Connor MB, Kingston RE, Simon JA: Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. Cell 2002;111:197-208.
13. Kirmizis A, Bartley SM, Farnham PJ: Identification of the polycomb group protein SU(Z)12 as a potential molecular target for human cancer therapy. Mol Cancer Ther 2003;2:113-121.
14. van Leenders GJ, Dukers D, Hessels D, van den Kieboom SW, Hulsbergen CA, Witjes JA, Otte AP, Meijer CJ, Raaphorst FM: Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol 2007;52:455-463.
15. Scott CL, Gil J, Hernando E, Teruya-Feldstein J, Narita M, Martinez D, Visakorpi T, Mu D, Cordon-Cardo C, Peters G, Beach D, Lowe SW: Role of the chromobox protein CBX7 in lymphomagenesis. Proc Natl Acad Sci USA 2007;104:5389-5394.
16. Sobin LH, Wittekind C: TNM Classification of Malignant Tumors, ed 6. New York, Wiley, 2002.
17. Epstein JI, Amin MB, Reuter VR, Mostofi FK: The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998;22:1435-1448.
18. Eble JN, Sauter G, Epstein JI, Sesterhenn IA: Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs; in World Health Organization Classification of Tumors. Lyon, IARC Press, 2004, vol 1.
19. Raman JD, Mongan NP, Tickoo SK, Boorjian SA, Scherr DS, Gudas LJ: Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin Cancer Res 2005;11:8570-8576.
20. Weikert S, Christoph F, Kollermann J, Muller M, Schrader M, Miller K, Krause H: Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int J Mol Med 2005;16:349-353.
21. Gil J, Bernard D, Peters G: Role of polycomb group proteins in stem cell self-renewal and cancer. DNA Cell Biol 2005;24:117-125.
22. Valk-Lingbeek ME, Bruggeman SW, van Lohuizen M: Stem cells and cancer;the polycomb connection. Cell 2004;118:409-418.
23. Gil J, Bernard D, Martinez D, Beach D: Polycomb CBX7 has a unifying role in cellular lifespan. Nat Cell Biol 2004;6:67-72.
24. Satijn DP, Olson DJ, van der Vlag J, Hamer KM, Lambrechts C, Masselink H, Gunster MJ, Sewalt RG, van Driel R, Otte AP: Interference with the expression of a novel human polycomb protein, hPc2, results in cellular transformation and apoptosis. Mol Cell Biol 1997;17:6076-6086.
25. Kanno M, Hasegawa M, Ishida A, Isono K, Taniguchi M: mel-18, a Polycomb group-related mammalian gene, encodes a transcriptional negative regulator with tumor suppressive activity. EMBO J 1995;14:5672-5678.
26. Guo WJ, Zeng MS, Yadav A, Song LB, Guo BH, Band V, Dimri GP: Mel-18 acts as a tumor suppressor by repressing Bmi-1 expression and down-regulating Akt activity in breast cancer cells. Cancer Res 2007;67:5083-5089.
27. Matsuo F, Yano K, Saito H, Morotomi K, Kato M, Yoshimoto M, Kasumi F, Akiyama F, Sakamoto G, Miki Y: Mutation analysis of the mel-18 gene that shows decreased expression in human breast cancer cell lines. Breast Cancer 2002;9:33-38.
28. Suarez-Merino B, Hubank M, Revesz T, Harkness W, Hayward R, Thompson D, Darling JL, Thomas DG, Warr TJ: Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3. Neuro Oncol 2005;7:20-31.
29. Koed K, Wiuf C, Christensen LL, Wikman FP, Zieger K, Moller K, von der Maase H, Orntoft TF: High-density single nucleotide polymorphism array defines novel stage and location-dependent allelic imbalances in human bladder tumors. Cancer Res 2005;65:34-45.
30. Bernard D, Martinez-Leal JF, Rizzo S, Martinez D, Hudson D, Visakorpi T, Peters G, Carnero A, Beach D, Gil J: CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus. Oncogene 2005;24:5543-5551.
31. Chang LL, Yeh WT, Yang SY, Wu WJ, Huang CH: Genetic alterations of p16INK4a and p14ARF genes in human bladder cancer. J Urol 2003;170:595-600.
32. Orlow I, Lacombe L, Hannon GJ, Serrano M, Pellicer I, Dalbagni G, Reuter VE, Zhang ZF, Beach D, Cordon-Cardo C: Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst 1995;87:1524-1529.
33. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995;55:4525-4530.
34. Gunster MJ, Raaphorst FM, Hamer KM, den Blaauwen JL, Fieret E, Meijer CJ, Otte AP: Differential expression of human Polycomb group proteins in various tissues and cell types. J Cell Biochem 2001;81:129-143.